Jennifer Hellawell

1.8k total citations · 5 hit papers
35 papers, 1.2k citations indexed

About

Jennifer Hellawell is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Jennifer Hellawell has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 11 papers in Surgery and 9 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Jennifer Hellawell's work include Lipid metabolism and disorders (11 papers), Lipoproteins and Cardiovascular Health (7 papers) and Apelin-related biomedical research (5 papers). Jennifer Hellawell is often cited by papers focused on Lipid metabolism and disorders (11 papers), Lipoproteins and Cardiovascular Health (7 papers) and Apelin-related biomedical research (5 papers). Jennifer Hellawell collaborates with scholars based in United States, Canada and Australia. Jennifer Hellawell's co-authors include Kenneth B. Margulies, Gerald F. Watts, Daniel Gaudet, Christie M. Ballantyne, Robert S. Rosenson, Martin S. Maron, Iacopo Olivotto, Ramin Farzaneh‐Far, Jaime C. Lucove and Javier San Martín and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Jennifer Hellawell

29 papers receiving 1.2k citations

Hit Papers

Preclinical development and phase 1 trial of a novel siRN... 2022 2026 2023 2024 2022 2024 2024 2024 2024 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
    2022 167 citations Michael J. Koren, Patrick M. Moriarty et al. profile →
  2. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
    2024 103 citations Robert S. Rosenson, Daniel Gaudet et al. New England Journal of Medicine profile →
  3. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
    2024 103 citations Christie M. Ballantyne, Szilárd Vasas et al. New England Journal of Medicine profile →
  4. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
    2024 90 citations Daniel Gaudet, Dénes Páll et al. JAMA Cardiology profile →
  5. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
    2024 66 citations Gerald F. Watts, Robert S. Rosenson et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Hellawell United States 16 526 426 340 207 175 35 1.2k
Rick E.W. van Leeuwen Netherlands 19 395 0.8× 323 0.8× 780 2.3× 63 0.3× 350 2.0× 24 1.5k
Shiraj Sen United States 16 385 0.7× 136 0.3× 544 1.6× 58 0.3× 129 0.7× 57 1.1k
Sakari Kakko Finland 17 83 0.2× 246 0.6× 366 1.1× 167 0.8× 114 0.7× 36 891
Tao Sun China 19 104 0.2× 187 0.4× 379 1.1× 335 1.6× 185 1.1× 92 1.4k
Brigitte Kaiser Germany 17 400 0.8× 377 0.9× 315 0.9× 44 0.2× 103 0.6× 61 1.6k
David G. Orloff United States 17 162 0.3× 274 0.6× 473 1.4× 197 1.0× 105 0.6× 26 1.5k
Mir Ali Reza Hoda Austria 11 111 0.2× 461 1.1× 227 0.7× 67 0.3× 50 0.3× 18 1.2k
Hiroshi Banno Japan 23 331 0.6× 334 0.8× 424 1.2× 21 0.1× 89 0.5× 93 1.6k
Gabriel P. Lasala United Kingdom 10 184 0.3× 690 1.6× 266 0.8× 388 1.9× 161 0.9× 14 1.0k
Shuguang Zhu China 17 153 0.3× 264 0.6× 493 1.4× 34 0.2× 240 1.4× 48 1.1k

Countries citing papers authored by Jennifer Hellawell

Since Specialization
Citations

This map shows the geographic impact of Jennifer Hellawell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Hellawell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Hellawell more than expected).

Fields of papers citing papers by Jennifer Hellawell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Hellawell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Hellawell. The network helps show where Jennifer Hellawell may publish in the future.

Co-authorship network of co-authors of Jennifer Hellawell

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Hellawell. A scholar is included among the top collaborators of Jennifer Hellawell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Hellawell. Jennifer Hellawell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Björnson, Elias, Chris J. Packard, Martin Adiels, et al.. (2025). Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3 silencing and predicts clinically relevant coronary heart disease event reductions. European Journal of Preventive Cardiology. 2 indexed citations
2.
3.
Watts, Gerald F., Robert A. Hegele, Robert S. Rosenson, et al.. (2025). PALISADE: PLOZASIRAN DECREASES THE RISK OF ACUTE PANCREATITIS AND MAY IMPROVE QUALITY OF LIFE IN FAMILIAL CHYLOMICRONEMIA SYNDROME. American Journal of Preventive Cardiology. 23. 101140–101140.
4.
5.
Vasas, Szilárd, Masoud Azizad, Peter Clifton, et al.. (2024). †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results. Journal of clinical lipidology. 18(4). e560–e560.
6.
Watts, Gerald F., Robert S. Rosenson, Robert A. Hegele, et al.. (2024). Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. New England Journal of Medicine. 392(2). 127–137. 66 indexed citations breakdown →
7.
Ballantyne, Christie M., Szilárd Vasas, Masoud Azizad, et al.. (2024). Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. New England Journal of Medicine. 391(10). 899–912. 103 indexed citations breakdown →
8.
9.
Gaudet, Daniel, Dénes Páll, Gerald F. Watts, et al.. (2024). Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia. JAMA Cardiology. 9(7). 620–620. 90 indexed citations breakdown →
10.
Rosenson, Robert S., Daniel Gaudet, Robert A. Hegele, et al.. (2024). Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. New England Journal of Medicine. 391(10). 913–925. 103 indexed citations breakdown →
11.
12.
13.
Trivedi, Ashit, et al.. (2022). Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986. Drugs in R&D. 22(1). 89–94. 4 indexed citations
14.
15.
Koren, Michael J., Patrick M. Moriarty, Joel Neutel, et al.. (2020). Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a). Circulation. 142(Suppl_3). 25 indexed citations
16.
Mussinelli, Roberta, Deepa M. Gopal, John L. Berk, et al.. (2019). Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Journal of Cardiac Failure. 26(9). 753–759. 77 indexed citations
17.
Maron, Martin S., Jennifer Hellawell, Jaime C. Lucove, Ramin Farzaneh‐Far, & Iacopo Olivotto. (2016). Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. The American Journal of Cardiology. 117(10). 1651–1654. 105 indexed citations
18.
Hellawell, Jennifer, et al.. (2014). Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension. Expert Opinion on Drug Metabolism & Toxicology. 10(10). 1445–1453. 4 indexed citations
19.
Ip, James E., Jim W. Cheung, David Park, et al.. (2010). Temporal Associations Between Thoracic Volume Overload and Malignant Ventricular Arrhythmias: A Study of Intrathoracic Impedance. Journal of Cardiovascular Electrophysiology. 22(3). 293–299. 26 indexed citations
20.
Hall, Matthew D., Noeris K. Salam, Jennifer Hellawell, et al.. (2009). Synthesis, Activity, and Pharmacophore Development for Isatin-β-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells. Journal of Medicinal Chemistry. 52(10). 3191–3204. 145 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rick E.W. van Leeuwen Breakdown of academic impact, for papers by Shiraj Sen Breakdown of academic impact, for papers by Sakari Kakko Breakdown of academic impact, for papers by Tao Sun Breakdown of academic impact, for papers by Brigitte Kaiser Breakdown of academic impact, for papers by David G. Orloff Breakdown of academic impact, for papers by Mir Ali Reza Hoda Breakdown of academic impact, for papers by Hiroshi Banno Breakdown of academic impact, for papers by Gabriel P. Lasala Breakdown of academic impact, for papers by Shuguang Zhu
Rankless by CCL
2026